Synchroneuron, Inc.

Following a new FDA approval, Teva Pharmaceutical Industries Ltd. is set for an immediate launch in the US of the vesicular monoamine 2 transporter (VMAT2) inhibitor Austedo in tardive dyskinesi

The US approval for Neurocrine Biosciences Inc. 's Ingrezza (valbenazine), without a black box warning, for the treatment of adults with tardive dyskinesia is the best possible scenario for the S

Tonix Pharmaceuticals Holding Corp. , founded in 2007 and based in New York, spent the first ten years of its life developing lead compound, TNX-102, for the treatment of chronic pain condition fibro

IN VITRO DIAGNOSTICS Epic Sciences Inc. Series C brings $30mm to Epic Sciences Epic Sciences Inc. (molecular diagnostics for cancer) closed a $30mm Series C round. New investors RusnanoMedInve